{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:34:20Z","timestamp":1771364060060,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.cgh.2019.07.020","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T11:30:16Z","timestamp":1563276616000},"page":"51-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis"],"prefix":"10.1016","volume":"18","author":[{"given":"Giulia","family":"Roda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-7902","authenticated-orcid":false,"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-3226","authenticated-orcid":false,"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2019.07.020_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2015.08.012","article-title":"The gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Eksteen","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2019.07.020_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2019.05.006","article-title":"Return to sender: lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis","volume":"71","author":"De Krijger","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2019.07.020_bib3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MEG.0000000000000596","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options","volume":"28","author":"Franceschet","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.07.020_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.07.020_bib5","first-page":"1","article-title":"The use of biologics in\u00a0patients with inflammatory bowel disease and primary sclerosing cholangitis","volume":"20","author":"Lynch","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2019.07.020_bib6","first-page":"1015408","article-title":"Tumor necrosis factor alpha inhibition for inflammatory bowel disease after liver transplant for primary sclerosing cholangitis","volume":"2018","author":"Parekh","year":"2018","journal-title":"Case Rep Gastrointest Med"},{"key":"10.1016\/j.cgh.2019.07.020_bib7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.07.020_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.07.020_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","author":"Chateau","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.07.020_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.07.020_bib11","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2019.07.020_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstr\u00f6m","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.07.020_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2019.07.020_bib14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/2050640619858050","article-title":"Safety of vedolizumab in liver transplant recipients: a systematic review","volume":"7","author":"Spadaccini","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2019.07.020_bib15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519307530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519307530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:27:40Z","timestamp":1761542860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356519307530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1542356519307530"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2019.07.020","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.05.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}